BioNTech co-created the Pfizer COVID vaccine, now focused on cancer.
BioNTech SE (BNTX) is expected to report earnings on Tuesday, November 3, 2026, after the close. Consensus EPS estimate is $0.86.
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| 2026-08-04 | FY2026 Q2 | $-2.40 | $-3.70 | -54.3% | $120.60M |
| 2026-05-05 | FY2026 Q1 | $-2.54 | $-2.43 | +4.4% | $136.45M |
| 2026-03-10 | FY2025 Q4 | $-0.22 | $-0.38 | -72.7% | $1.07B |
| 2025-11-03 | FY2025 Q3 | $-1.12 | $-0.14 | +87.5% | $1.78B |
| 2025-08-04 | FY2025 Q2 | $-2.69 | $-1.82 | +32.3% | $307.08M |
| 2025-05-05 | FY2025 Q1 | $-2.48 | $-1.82 | +26.5% | $200.39M |
| 2025-03-10 | FY2024 Q4 | $0.46 | $1.15 | +148.7% | $1.23B |
| 2024-08-05 | FY2024 Q2 | $-2.19 | $-3.62 | -65.2% | $138.38M |
BNTX has beaten consensus EPS in 5 of its last 8 reported quarters.
BNTX reported Aug 4. The highlights: EPS of -$3.70 — a sharp miss vs the -$2.40 estimate (-54%); revenue of $121M — a sharp miss vs the $180M consensus (-33%). Focus now shifts to oncology pipeline milestones.
See BNTX on the live calendar →